Neddylation inhibitor, BCL-2 inhibitor, and IKK inhibitor as Breast Cancer Treatments

Linda CuiFollow

School Name

Chapin High School

Grade Level

11th Grade

Presentation Topic

Cell and Molecular Biology

Presentation Type

Mentored

Abstract

Breast cancer, along with lung, colon, rectum, and prostate cancer are the most common types of cancer making up 50% of all cancer diagnosises, with breast cancer alone making about 30% of all cancer diagnosises. Over the past few decades, there has been a lot of research on what drugs can lead to breast cancer cells dying. One of the drugs tested was Neddylation inhibitor MLN4924, which was found to increase the rate of apoptosis in cancer cells, but further research has shown that some cell lines are resistant to the drug. This project will research the effects of MLN4924 when it is being used with BCL-2 inhibitor ABT-199 and IKK inhibitor BAY 11-7082 in cell lines MCF-7 and MDA-MB-231. This experiment will use a varying amount of each inhibitor and add it to each cell line before being dyed with Annexin V or TMRE. Annexin V will show the rate of apoptosis (cell death) and TMRE will show the rate of mitochondrial membrane potential (stress on the membrane that may lead to apoptosis) within a sample after being run through a flow cytometer. After conducting this experiment, while both ABT-199 and BAY 11-7082 showed an increase in the rate of apoptosis and an effect on the rate of mitochondrial membrane potential, BAY 11-7082 having a larger increase, neither had a very significant effect on the cell lines.

Location

RITA 271

Start Date

3-23-2024 9:45 AM

Presentation Format

Oral and Written

Group Project

No

COinS
 
Mar 23rd, 9:45 AM

Neddylation inhibitor, BCL-2 inhibitor, and IKK inhibitor as Breast Cancer Treatments

RITA 271

Breast cancer, along with lung, colon, rectum, and prostate cancer are the most common types of cancer making up 50% of all cancer diagnosises, with breast cancer alone making about 30% of all cancer diagnosises. Over the past few decades, there has been a lot of research on what drugs can lead to breast cancer cells dying. One of the drugs tested was Neddylation inhibitor MLN4924, which was found to increase the rate of apoptosis in cancer cells, but further research has shown that some cell lines are resistant to the drug. This project will research the effects of MLN4924 when it is being used with BCL-2 inhibitor ABT-199 and IKK inhibitor BAY 11-7082 in cell lines MCF-7 and MDA-MB-231. This experiment will use a varying amount of each inhibitor and add it to each cell line before being dyed with Annexin V or TMRE. Annexin V will show the rate of apoptosis (cell death) and TMRE will show the rate of mitochondrial membrane potential (stress on the membrane that may lead to apoptosis) within a sample after being run through a flow cytometer. After conducting this experiment, while both ABT-199 and BAY 11-7082 showed an increase in the rate of apoptosis and an effect on the rate of mitochondrial membrane potential, BAY 11-7082 having a larger increase, neither had a very significant effect on the cell lines.